Floatz logo

Telotristat Ethyl

Neuroendocrine Neoplasm

Andrew Hendifar, MDSmall moleculeUnknownDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

59 Active assets in the Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
Cabozantinib
Fox Chase Cancer Center
Phase 3BB
Fluorouracilum
ITM Solucin GmbH
Phase 3BB
Xaliplatin
ITM Solucin GmbH
Phase 3BB
Everolimus
Exelixis
Phase 3BB

View all 50 →

Same molecule, other indications

Telotristat Ethyl is also rated in:

pancreatic adenocarcinomaDormant
B
Indicative · Phase 2
57 / 100
View asset →
malignant pancreatic neoplasmDormant
B
Indicative · Phase 2
57 / 100
View asset →
carcinoid syndromeDormant
CC
Indicative · Phase 1
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →